240 related articles for article (PubMed ID: 21624422)
1. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.
Hammitt LL; Campbell JC; Borys D; Weatherholtz RC; Reid R; Goklish N; Moulton LH; Traskine M; Song Y; Swinnen K; Santosham M; O'Brien KL
Vaccine; 2019 Dec; 37(51):7482-7492. PubMed ID: 31629570
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.
Odutola A; Ota MO; Ogundare EO; Antonio M; Owiafe P; Worwui A; Greenwood B; Alderson M; Traskine M; Verlant V; Dobbelaere K; Borys D
Hum Vaccin Immunother; 2016; 12(2):393-402. PubMed ID: 26618243
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
[TBL] [Abstract][Full Text] [Related]
6. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
[TBL] [Abstract][Full Text] [Related]
8. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
Verhoeven D; Perry S; Pichichero ME
Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen.
Hermand P; Vandercammen A; Mertens E; Di Paolo E; Verlant V; Denoël P; Godfroid F
Hum Vaccin Immunother; 2017 Jan; 13(1):220-228. PubMed ID: 27768518
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
[TBL] [Abstract][Full Text] [Related]
11. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
Xu Q; Pryharski K; Pichichero ME
Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
[TBL] [Abstract][Full Text] [Related]
14. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
[TBL] [Abstract][Full Text] [Related]
15. Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.
Moens L; Hermand P; Wellens T; Wuyts G; Derua R; Waelkens E; Ysebaert C; Godfroid F; Bossuyt X
Hum Vaccin Immunother; 2018 May; 14(5):1234-1242. PubMed ID: 29400602
[TBL] [Abstract][Full Text] [Related]
16. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.
Xu Q; Surendran N; Verhoeven D; Klapa J; Ochs M; Pichichero ME
Vaccine; 2015 Feb; 33(8):993-1000. PubMed ID: 25597944
[TBL] [Abstract][Full Text] [Related]
17. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
[TBL] [Abstract][Full Text] [Related]
19. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
[No Abstract] [Full Text] [Related]
[Next] [New Search]
